Summary
Global Markets Direct’s, ‘Acceleron Pharma, Inc. - Product Pipeline Review - 2016’, provides an overview of the Acceleron Pharma, Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Acceleron Pharma, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Acceleron Pharma, Inc.
- The report provides overview of Acceleron Pharma, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Acceleron Pharma, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Acceleron Pharma, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Acceleron Pharma, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acceleron Pharma, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acceleron Pharma, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Acceleron Pharma, Inc. Snapshot 6
Acceleron Pharma, Inc. Overview 6
Key Information 6
Key Facts 6
Acceleron Pharma, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Acceleron Pharma, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Acceleron Pharma, Inc. - Pipeline Products Glance 12
Acceleron Pharma, Inc. - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
Acceleron Pharma, Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Acceleron Pharma, Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Acceleron Pharma, Inc. - Drug Profiles 16
luspatercept 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
dalantercept 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
sotatercept 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
ACE-083 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ACE-1332 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ACE-2395 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
ACE-2494 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ACE-2536 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ACE-2798 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ACE-3891 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ACE-661 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Acceleron Pharma, Inc. - Pipeline Analysis 30
Acceleron Pharma, Inc. - Pipeline Products by Target 30
Acceleron Pharma, Inc. - Pipeline Products by Route of Administration 31
Acceleron Pharma, Inc. - Pipeline Products by Molecule Type 32
Acceleron Pharma, Inc. - Pipeline Products by Mechanism of Action 33
Acceleron Pharma, Inc. - Recent Pipeline Updates 34
Acceleron Pharma, Inc. - Dormant Projects 44
Acceleron Pharma, Inc. - Discontinued Pipeline Products 45
Discontinued Pipeline Product Profiles 45
ramatercept 45
Acceleron Pharma, Inc. - Locations And Subsidiaries 46
Head Office 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48
List of Tables
Acceleron Pharma, Inc., Key Information 6
Acceleron Pharma, Inc., Key Facts 6
Acceleron Pharma, Inc. - Pipeline by Indication, 2016 8
Acceleron Pharma, Inc. - Pipeline by Stage of Development, 2016 10
Acceleron Pharma, Inc. - Monotherapy Products in Pipeline, 2016 11
Acceleron Pharma, Inc. - Phase III, 2016 12
Acceleron Pharma, Inc. - Phase II, 2016 13
Acceleron Pharma, Inc. - Phase I, 2016 14
Acceleron Pharma, Inc. - Preclinical, 2016 15
Acceleron Pharma, Inc. - Pipeline by Target, 2016 30
Acceleron Pharma, Inc. - Pipeline by Route of Administration, 2016 31
Acceleron Pharma, Inc. - Pipeline by Molecule Type, 2016 32
Acceleron Pharma, Inc. - Pipeline Products by Mechanism of Action, 2016 33
Acceleron Pharma, Inc. - Recent Pipeline Updates, 2016 34
Acceleron Pharma, Inc. - Dormant Developmental Projects,2016 44
Acceleron Pharma, Inc. - Discontinued Pipeline Products, 2016 45
List of Figures
Acceleron Pharma, Inc. - Pipeline by Top 10 Indication, 2016 8
Acceleron Pharma, Inc. - Pipeline by Stage of Development, 2016 10
Acceleron Pharma, Inc. - Monotherapy Products in Pipeline, 2016 11
Acceleron Pharma, Inc. - Pipeline by Top 10 Target, 2016 30
Acceleron Pharma, Inc. - Pipeline by Top 10 Route of Administration, 2016 31
Acceleron Pharma, Inc. - Pipeline by Top 10 Molecule Type, 2016 32
Acceleron Pharma, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 33
